News | Heart Valve Technology | October 04, 2019

Study Finds Sustained Benefit for TAVR vs. SAVR at One Year

Results from the PARTNER 3 Quality of Life Sub-study presented at TCT 2019

A Sapien 3 TAVR valve in position as seen under GE Assist guidance on angiography. Study Finds Sustained Benefit for TAVR vs. SAVR at One Year. #TCT2019 #TCT19

A Sapien 3 TAVR valve in position as seen under GE Assist guidance on angiography.

October 4, 2019 – A new analysis of the PARTNER 3 Trial data found a modest, but significant, improvement in one-year disease-specific quality of life after transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement (SAVR) in low-risk patients with severe aortic stenosis (AS). Findings were reported at the 2019 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. The results were also published simultaneously in the Journal of the American College of Cardiology.[1]

The randomized PARTNER 3 trial demonstrated that TAVR with the Sapien 3 valve resulted in lower rates of death, and re-hospitalization at one year compared with SAVR in patients with severe AS at low surgical risk. However, the effect of treatment strategy on early and late health-related quality of life in this population is unknown.

“This is the first randomized trial to demonstrate a persistent, albeit modest, disease-specific health status advantage with TAVR at six and 12 months – time points at which patients are assumed to have recovered fully from surgery,” said Suzanne J. Baron, M.D., MSc, director of interventional cardiology research at Lahey Hospital and Medical Center in Burlington, Mass. “Further studies are needed to evaluate the durability of health status benefits with TAVR compared with SAVR beyond one year in this low-risk population.”

The researchers compared health status at one, six and 12 months in low risk patients with severe AS treated with either TAVR or SAVR in the PARTNER 3 trial. The analysis found that over the one-year follow-up period, treatment with either TAVR or SAVR resulted in substantial improvements in both disease-specific and generic health status compared with baseline, despite most patients having only NYHA Class I or II symptoms at baseline. Consistent with previous studies of transfemoral TAVR, TAVR was associated with significantly better health status than SAVR at one month on all scales (mean difference in KCCQ-OS 16.0 points; p<0.001). However, in contrast to prior studies, the researchers observed a persistent, although attenuated, benefit of TAVR over SAVR in disease-specific health status at six and 12 months (mean difference in KCCQ-OS 2.6 and 1.8 points respectively; p<0.04 for both).

In analyses that incorporated both survival and change in health status together, TAVR also demonstrated a significant health status benefit compared with SAVR at all time points (p<0.05). 

Exploratory analyses demonstrated that the late health status benefits seen with TAVR were driven by a difference in the proportion of patients who experienced a large (i.e., ≥20 point) improvement in the KCCQ score. These benefits may be explained, in part, by differential rates of post-procedural complications between TAVR and SAVR.

The PARTNER 3 Quality of Life Substudy was funded by Edwards Lifesciences. Baron disclosed research funding and advisory board compensation from Boston Scientific Corp and consulting fees from Edwards Lifesciences. 

Find information on other late-breaking TCT trials

Reference:

1. Suzanne J. Baron, Elizabeth A. Magnuson, Michael Lu, et al. Health Status after Transcatheter vs. Surgical Aortic Valve Replacement in Low-Risk Patients with Aortic Stenosis. Journal of the American College of Cardiology. September 2019. DOI: 10.1016/j.jacc.2019.09.007

 

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init